Zoetis Inc.

Pharmaceutical Preparations·PARSIPPANY, NJ·FY end 12/31·CIK 1555280

CEO Pay Ratio

236:1

Kristin C. Peck

CEO Total Comp

—

Kristin C. Peck

Median Employee

—

Revenue

$9.5B

FY 2025

Net Income

$2.7B

FY 2025

Free Cash Flow

$2.3B

FY 2025

Net Margin

28.2%

Insider Net (180d)

0 buys / 0 sales

CEO Pay Accountability

CEO comp as % of net income

—

Not enough data to compute.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$9.5B	$9.3B	$8.5B	$8.1B	$7.8B
Gross Profit	—	—	—	—	—	—
Operating Income	—	—	—	—	—	—
Net Income	$2.7B	$2.5B	$2.3B	$2.1B	$2.0B
Operating CF	$2.9B	$3.0B	$2.4B	$1.9B	$2.2B
Capex	$621.0M	$655.0M	$732.0M	$586.0M	$477.0M
Free Cash Flow	$2.3B	$2.3B	$1.6B	$1.3B	$1.7B
Buybacks	$248.0M	$1.9B	$1.1B	$1.6B	$743.0M
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—
Net Margin	28.2%	26.9%	27.4%	26.2%	26.2%
FCF Margin	24.1%	24.8%	19.0%	16.4%	22.3%
R&D / Revenue	—	—	—	—	—	—
Effective Tax	20.4%	20.3%	20.3%	20.5%	18.2%
Debt / Equity	2.71	1.09	1.31	1.49	1.45
Buybacks / FCF	10.9%	80.9%	67.4%	120.2%	42.8%

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Jamie Brannan	—	—	—	—	—	—
Kristin C. PeckChief Executive Officer	$1.4M	$3.4M	$2.2M	$12.1M	$19.0M	—
Robert J. PolzerFormer EVP and President of Research and Development	$710.0K	$555.5K	$590.7K	$1.8M	$3.7M	—
Robert PolzerEVP and President, Research and Development	—	—	—	—	—	—
Roxanne LaganoEVP, General Counsel and Corporate Secretary	$700.0K	$347.5K	$604.8K	$1.2M	$2.8M	—
Wetteny JosephExecutive Vice President (“EVP”) and Chief Financial Officer	$800.0K	$950.0K	$832.0K	$3.0M	$5.6M	—